ClinicalTrials.gg
RecruitingNCT05661903Updated Aug 20, 2026

From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects

A Phase 2 interventional study of Spinal Cord Stimulator Set to Minimal/No Stimulation Setting and Usual Care in Chronic Pain, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Chronic Pain by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Chronic Pain · Massachusetts General Hospital.

Planned enrollment
4th of 23
180 · median 60
Started
2023
with 3 others
Phase 2
2 of 27
2 open now
Registered
16th of 27
by date

Among the 27 studies in Chronic Pain by Massachusetts General Hospital, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 in phase 2, and was the 16th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

7 of the 27 studies in Chronic Pain by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Chronic Pain by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography/magnetic resonance imaging at baseline, week 2 and week 4.

Read the detailed description

The fundamental hypothesis for this study is that spinal cord stimulators modulate the excitability of primary afferent neurons to reduce pain, and that these changes can be detected by measurement of axonal excitability. For the primary outcome, the study investigators will leverage the sensitivity and reproducibility of threshold tracking nerve conduction studies to detect changes in the excitability of thickly myelinated nerve fibers. The study investigators will use microneurography to record directly from primary nociceptive afferents. Finally, the study investigators will perform plasma inflammatory cytokine profiles to measure changes due to spinal cord stimulators. By correlating changes in outcome measurements with subject pain levels during therapeutic versus minimal spinal cord stimulators settings, this study will determine which effects may be mechanistically relevant and which are unrelated to reduction in pain. Thus, this study will use robust, reproducible techniques to define the peripheral, central, and systemic effects of spinal cord stimulators.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80
  • Capable of providing and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes
  • Stably implanted spinal cord or dorsal root ganglion stimulator
  • Device is to treat back/radicular lower extremity pain or neck/arm pain
  • Device with a paresthesia-free setting

Exclusion criteria

Exclusion Criteria:

  • Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME/day per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study
  • The investigator concludes that the participant is unable to differentiate back or neck/arm pain from other pains
  • Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial
  • Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures

Dropout Criteria for Optional Imaging

  • Stimulation device is not 3 Tesla magnetic resonance imaging compliant
  • to magnetic resonance imaging and/or positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
  • Pregnant or breastfeeding
  • Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.
  • Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.
  • Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee
  • In the opinion of the investigators, unable to safely participate in this study and/or provide reliable data (e.g., unlikely to remain still during the imaging procedures).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Other
    Patients with Implanted Devices on Minimal/No Stimulation Settings

    Patients in this arm will be randomized to turn off their spinal cord stimulator (or to minimal settings).

    Other: Spinal Cord Stimulator Set to Minimal/No Stimulation Setting · Drug: Positron Emission Tomography / Magnetic Resonance Imaging

  • Other
    Patients with Implanted Devices on Usual Stimulation Settings

    Patients in this arm will be randomized to turn on their spinal cord stimulator to their usual stimulation settings.

    Other: Usual Care · Drug: Positron Emission Tomography / Magnetic Resonance Imaging

Interventions

  • OtherSpinal Cord Stimulator Set to Minimal/No Stimulation Setting

    Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.

  • OtherUsual Care

    Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.

  • DrugPositron Emission Tomography / Magnetic Resonance Imaging

    Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.

06

What researchers measure

Primary outcomes

  1. Supraexcitability

    The primary outcome will be superexcitability (indicating paired pulse facilitation) measured by threshold tracking nerve conduction.

    Time frame: From baseline (enrollment) to six weeks

07

Study locations

3 of 3 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Brian Wainger, MD PhD · Contact
    • Marco Loggia, PhD · Sub investigator
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Roy Freeman, MD · Contact
  • Brigham and Women's Hospital
    Boston, Massachusetts 02215, United States
    Recruiting
    • Christopher Gilligan, MD · Contact
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Aug 2027, 50 months after the start.

Of 47 non-industry phase 2 interventional studies under Chronic Pain, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 50 months is above that.

Counting every sponsor, half of 60 studies reached it within 37 months; a quarter within 21 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 22, 2022
StartActual
Jun 8, 2023
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05661903
Responsible party
Brian Wainger (Assistant Professor in Anesthesiology and Neurology, Massachusetts General Hospital) — Principal investigator
First posted
Dec 22, 2022
Start date
Jun 8, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Brian Wainger, MD PhD
Contact
BWAINGER@PARTNERS.ORG
617-726-8810
Brian Wainger, MD PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion